Latest Pharma and Biotech News
Biotechnology
26 November 2024 US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement.
Today's issue
Refine Search
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Pharmaceutical
Positive top-line results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality, were released today by US pharma giant Merck & Co. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers, from privately-held US-Ireland-based pharmaceutical company Shorla Oncology. 25 November 2024
Pharmaceutical
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
Pharmaceutical
Levothyroxine, a widely prescribed treatment for hypothyroidism, may contribute to bone loss in older adults, according to new research presented at the Radiological Society of North America’s (RSNA) annual meeting. 25 November 2024
All news
Biotechnology
Announcing its first M&A deal in more than a year, California, USA-based Gilead Sciences said yesterday that it has acquired privately-held US biotech XinThera. 10 May 2023
Biotechnology
Privately-held Chinese biotech Zion Pharma revealed that Swiss pharms giant Roche has acquired the global rights to Zion’s lead program, ZN-A-1041, an orally administered selective tyrosine kinase inhibitor targeting the human epidermal growth factor receptor 2 (HER2). 10 May 2023
Generics
Effective June 1, 2023, prescribing of oral ivermectin for ‘off-label’ uses will no longer be limited to specialists such as dermatologists, gastroenterologists and infectious diseases specialists, in Australia. 10 May 2023
Biotechnology
US biopharma Insmed yesterday announced progress across its early-stage research programs, at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More. 10 May 2023
Biotechnology
In line with a trend for big life science firms to divest non-core operations, medtech giant Baxter International (NYSE: BAX) is to sell off its biopharma manufacturing unit. 10 May 2023
Biotechnology
US drugmaker EQRx had already signalled a shift away from its foundational principle to develop and deliver innovative medicines to patients at radically lower prices. 9 May 2023
Biotechnology
The World Health Organization’s (WHO) declaration on Friday that the COVID-19 global emergency status has ended, and that the virus should now be managed alongside other infectious diseases, formally brings to an end what has been an uncertain and difficult time for much of the world. 9 May 2023
Biotechnology
A new Fabry disease therapy, PRX-102 (pegunigalsidase alfa), has been given marketing authorization by the European Medicines Agency. 9 May 2023
Pharmaceutical
A bumper month of M&A activity in March gave way to one with just three acquisitions in April - albeit two of those were multi-billion dollar deals. 9 May 2023
Biotechnology
Japanese drugmaker Eisai has entered into an agreement with Chinese firm Bliss Biopharmaceutical to develop an antibody-drug conjugate (ADC). 9 May 2023
Biotechnology
Spanish dermatology company Almirall has recorded net sales of 230 million euros ($253 million) in the first quarter of 2023, a 6% increase, and net income of 7.7 million euros. 9 May 2023
Generics
India’s Venus Remedies has won separate marketing authorizations for off-patent cancer drugs in the Philippines and Iraq. 9 May 2023
Pharmaceutical
The UK’s largest drugmaker, AstraZeneca, has secured an additional approval in the USA for its heart med Farxiga (dapagliflozin). 9 May 2023
Pharmaceutical
German drugmaker Bayer (BAYN: DE) has announced the inauguration of its new life science incubator in Kendall Square, Cambridge, Massachusetts. 5 May 2023
Biotechnology
The poor execution of a Phase III trial in Lyme disease has set back plans to submit vaccine candidate VLA15 for regulatory approval in the USA. 5 May 2023
Pharmaceutical
Roche has announced the launch of the Institute of Human Biology (IHB), focussing on advancing research in the field of human model systems such as organoids. 5 May 2023
Biotechnology
US mRNA specialist Moderna has reported first-quarter revenues of $1.86 billion. 5 May 2023
Biotechnology
The UK’s biggest drugmaker, AstraZeneca, has terminated a collaboration with oncolytic virus company Transgene. 5 May 2023
Pharmaceutical
The renegotiation of the UK’s Voluntary Pricing and Access Scheme (VPAS) has begun. 4 May 2023
Biotechnology
Regeneron was trading 7% lower on Thursday lunchtime following the presentation of its first-quarter 2023 financial results and latest guidance for the full-year. 4 May 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze